AKARI THERAPEUTICS PLC-ADR (AKTX) Forecast, Price Target & Analyst Ratings
NASDAQ:AKTX • US00972G2075
0.253 USD
+0.01 (+2.6%)
Last: Mar 6, 2026, 02:39 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for AKARI THERAPEUTICS PLC-ADR (AKTX).
Forecast Snapshot
Consensus Price Target
$2.96
+ 1,069.17% Upside
Next Earnings Forecast
Release DateApr 13, 2026
PeriodQ4 / 2025
EPS Estimate-$0.04
Revenue Estimate
ChartMill Buy Consensus
84.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$2.96
Upside
+ 1,069.17%
From current price of $0.25 to mean target of $2.96, Based on 10 analyst forecasts
Low
$1.01
Median
$1.84
High
$7.35
Price Target Revisions
1 Month
-20.55%
3 Months
-36.03%
Price Target Summary
10 analysts have analysed AKTX and the average price target is 2.96 USD. This implies a price increase of 1069.17% is expected in the next year compared to the current price of 0.253.
The average price target has been revised downward by 36.03% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.00%
AKTX was analyzed by 10 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about AKTX.
In the previous month the buy percentage consensus was at a similar level.
AKTX was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-05 | Ladenburg Thalmann | Initiate | Buy |
| 2025-09-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-18 | Maxim Group | Initiate | Buy |
| 2022-12-05 | HC Wainwright & Co. | Initiate | Buy |
| 2022-11-01 | Alliance Global Partners | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 13, 2026
PeriodQ4 / 2025
EPS Estimate-$0.04
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q96.25%
Number of Analysts6
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
37.50%
Next Earnings Summary
AKTX is expected to report earnings on 4/13/2026. The consensus EPS estimate for the next earnings is -0.04 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A 748.98% | N/A 99.87% | N/A 42.21% | |||||||||||
| EBITDA YoY % growth | -30.58M | -27.21M 11.02% | -35.04M -28.78% | -23.45M 33.08% | -16.94M 27.76% | -17.97M -6.08% | -17.21M 4.23% | -23.09M -34.17% | -16.802M 27.23% | -16.633M 1.01% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -30.59M | -27.25M 10.92% | -35.08M -28.73% | -23.49M 33.04% | -16.96M 27.80% | -17.98M -6.01% | -17.21M 4.28% | -23.09M -34.17% | -16.806M 27.22% | -16.647M 0.95% | N/A 26.81% | N/A -22.06% | N/A -34.58% | N/A -62.41% | N/A -9.85% | N/A -2.71% | N/A 58.46% | N/A 256.18% | N/A 143.34% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -1.80 | -60.00 -3,233.33% | N/A 66.00% | -18.60 8.82% | N/A 98.90% | N/A 91.28% | N/A -34,318.85% | N/A 33.33% | N/A 15.00% | N/A 95.00% | N/A 14.71% | N/A -12.07% | N/A | N/A | N/A | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.04 96.25% | -0.03 | -0.02 | -0.03 | -0.04 -6.67% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -2.876M 33.04% | -3.379M 4.13% | -3.82M -22.47% | -4.657M -109.41% | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
24.98%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
AKARI THERAPEUTICS PLC-ADR / AKTX Forecast FAQ
What is the average price target for AKARI THERAPEUTICS PLC-ADR (AKTX) stock?
10 analysts have analysed AKTX and the average price target is 2.96 USD. This implies a price increase of 1069.17% is expected in the next year compared to the current price of 0.253.
Can you provide the upcoming earnings date for AKARI THERAPEUTICS PLC-ADR?
AKARI THERAPEUTICS PLC-ADR (AKTX) will report earnings on 2026-04-13, after the market close.
What are the consensus estimates for AKTX stock next earnings?
The consensus EPS estimate for the next earnings of AKARI THERAPEUTICS PLC-ADR (AKTX) is -0.04 USD and the consensus revenue estimate is 0 USD.
Can you provide the consensus rating for AKARI THERAPEUTICS PLC-ADR stock?
The consensus rating for AKARI THERAPEUTICS PLC-ADR (AKTX) is 84 / 100 . This indicates that analysts generally have a positive outlook on the stock.